ArticleNPJ breast cancer2024
Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
Sara A Hurvitz et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
40 papers cite it
this paperpooled itcites it